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ABSTRACT
We conducted a study to determine the main traits of pertussis among unimmunized infants less than
6 months of age. From August 2012 to March 2015, 141 nasopharyngeal aspirates (NPAs) were collected
from infants with respiratory symptoms attending 2 major hospitals in Rome. Clinical data were recorded
and analyzed. Lab-confirmation was performed by culture and realtime PCR. B. pertussis virulence-
associated genes (ptxP, ptxA and prn), together with multilocus variable-number tandem repeat analysis
(MLVA), were also investigated by the sequence-based analysis on the DNAs extracted from positive
samples. Antibiotic susceptibility with Etest was defined on 18 viable B. pertussis isolates. Samples from 73
infants resulted positives for B. pertussis. The median age of the patients was 45 d (range 7–165); 21 infants
were treated with macrolides before hospital admission. Cough was reported for a median of 10 d before
admission and 18 d after hospital discharge among infected infants, 84% of whom showed paroxysmal
cough. No resistance to macrolides was detected. Molecular analysis identified MT27 as the predominant
MLVA profile, combined with ptxP3-ptxA1-prn2 associated virulence genes.
Although our data may not be generalized to the whole country, they provide evidence of disease
severity among infants not vaccinated against pertussis. Moreover, genetically related B. pertussis strains,
comprising allelic variants of virulence associated genes, were identified.
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Introduction
Bordetella pertussis is the etiological agent of whooping cough
or pertussis. It primarily affects children less than 6 months of
age with severe clinical symptoms, causing an excess of admis-
sions to intensive care units. The most common manifestations
of B. pertussis infection are whooping cough and bronchitis,
with complications including pneumonia, seizures, encepha-
lopathy, and possibly sudden infant death.1
Pertussis is a vaccine-preventable disease. However, despite
the large use of primary immunization, outbreaks have been
reported also in countries with a high vaccination coverage.2
Several reports recognized in the waning immunity and in the
circulation of variants B. pertussis strains possible determinants
of the re-emergence of pertussis.3 Moreover, the circulation
among households4-6 could contribute to the transmission of
the disease to infants too young to be vaccinated. Finally, the
current risk for infant in the first months after birth and the
crucial role of a pertussis booster in pregnancy may certainly
be the key to address strategies to prevent infant death.
The disease is increasing due to many factors, including the
circulation of variants among B. pertussis isolates carrying viru-
lence associated genes different from the vaccine strains. In
particular, the promoter region of pertussis toxin (ptxP), the
region encoding the subunit S1 of the toxin (ptxA) and pertac-
tin (prn) genes, are the main gene targets analyzed in the circu-
lating pertussis isolates as acellular vaccine (ACV) components.
In Europe, the European Centre for Disease Control and
Prevention (ECDC)-funded network, Eupert-labnet, reported a
very similar B. pertussis population for 12 countries using
ACVs; in particular, circulating strains are distinct from vaccine
strain with respect of one or more virulence associated genes.7
In Italy, pertussis vaccination coverage is estimated to be
around 95%.8 Actually, the pertussis ACV is offered free of
charge, being included in the hexavalent vaccine, in combina-
tion with other vaccines against diphtheria, tetanus, polio, hep-
atitis b and Haemophilus influenzae type b. An incidence rate
of pertussis of 1 per 100,000 inhabitants has been reported in
2009 in the overall population in our country.9
Techniques for the early recognition of B. pertussis, such as
culture or molecular methods, are not always available, thus
under-diagnosis and under-reporting of pertussis often occur;
rapid and accurate diagnostic tests for pertussis are needed for
improved management of cases and protection especially for
infants.
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The main objective of our study was to estimate the propor-
tion of infants hospitalized with suspected pertussis, defined by
using the ECDC case definition,10 who are confirmed to be pos-
itive for B. pertussis by using appropriate laboratory diagnostic
tests. Clinical symptoms and virulence associated gene variants
were also evaluated among those with confirmed pertussis.
Results
A total of 73 out of the 141 enrolled children (51.8%) resulted
positive for B. pertussis. Of the 73 confirmed cases, 75% were
confirmed only by PCR, and 25% by both PCR and culture.
The median age of confirmed cases was 45 d (range 7–165); of
them, 12% had received one dose of vaccine, and 4% 2 doses,
before the date of disease onset. A significantly statistical differ-
ence (p < 0.05) was found between male:female ratio in infants
positive or negative for B. pertussis (Table 1).
Paroxysmal cough was more likely reported among children
with positive samples (OR 1.96; p < 0.05). A statistically signifi-
cant OR of 2.39 for post-cough vomiting, together with cyanosis
and apnea, was found for pertussis positive infants compared with
the others. Other respiratory infections were detected in 32 out of
68 negative samples (47%) and in 32 out of 73 positive samples
(43.8%): respiratory syncytial virus (RSV) and rhinovirus were the
most frequently agents diagnosed. No other Bordetellae as B. para-
pertussis, B. bronchiseptica and B. holmesii were detected.
Antimicrobial susceptibility against macrolides was assessed
for 18 B. pertussis isolates. Figure 1 showed the MIC values to
azithromycin (A), clarithromycin (B), and erythromycin (C);
MIC50 was 0.023, 0.380 and 0.094 mg/l and MIC90 0.064,
0.500 and 0.125 mg/l, respectively.
Furthermore, 56 of the 73 positive B. pertussis samples, were
molecularly characterized. PtxA1 was detected in all samples.
Fifty-four samples carried ptxP3 and 2 the ptxP1 allele. More-
over, the pertactin variable regions11 analysis revealed the pres-
ence of prn2 allele. MLVA typing and the entire pertactin gene
sequencing12 were performed on 18 pertussis viable isolates. As
shown in Table 2, MT27 profile was the predominant (16/18)
and mainly combined with ptxP3-ptxA1-prn2 genetic profile.
In 9 samples it was identified the pertactin deficient gene due
to the presence of the IS481 at nucleotide position 1613 or due
to other modifications (data not shown).12
MT28 and MT60 were represented by a single isolate, asso-
ciated with ptxP3-ptxA1-prn2 and ptxP1-ptxA1-prn2 profiles,
respectively.
Table 1. Demographic (A) and clinical characteristics (B) of the 141 infants with
lower respiratory infection, positive or negative for pertussis lab-confirmation.
(A) Demografic Characteristics
Pertussis
positive
Pertussis
negative p value OR
Case n 73 68 — —
Age; median in days (range) 45 (7–165) 49 (7–152) — —
Male:Female 44/29 28/40 <0.05 2.14
Vaccination 1 dose n (%) 9 (12) 4 (6) >0.05 1.13
Vaccination 2 doses n (%) 3 (4) 0 (0) — —
Macrolide before admission n
(%)
21 (29) 10 (15) >0.05 1.09
Steroid before admission n
(%)
31 (43) 16 (25) >0.05 1.13
(B) Clinical Characteristics
Pertussis
positive
Pertussis
negative p value OR
Case n 73 68 —
Cough at admission;
median in days (range)
10 (0–44) 4 (0–48) —
Cough after discharge;
median in days (range)
18 (0–100) 7 (4–30) —
Hospitalization; median
in days (range)
7 (1–41) 4 (0–36) —
Cough n (%) 67 (92) 65 (96) >0.05 0.96
Paroxysmal cough n (%) 61 (84) 29 (44) <0.05 1.96
Postussive vomiting n (%) 41 (56) 16 (24) <0.05 2.39
Cyanosis n (%) 42 (56) 12 (18) <0.05 13.5
Apnea n (%) 55 (75) 15 (23) <0.05 13.6
Fever n (%) 13 (18) 32 (47) >0.05 0.4
Figure 1. Distribution of Minimal Inhibitory Concentration (MIC) in mg/l for azi-
thromycin (A), clarithromycin (B) and erythromycin (C) of 18 Bordetella pertussis
strains.
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Discussion
Pertussis represents a re-emergent public health issue especially
for infants too young to be vaccinated. A study conducted by
van Hoek13 in England and Wales in 2001–2011 reported 48
deaths due to pertussis, among infants under 1 y of age. When
most cases occur in the first months of life, immunizing preg-
nant women could represent a successful strategy to protect
infant by transferring maternal antibodies.14
In Italy, the vaccination against pertussis has been recom-
mended since 1962 with the cellular pertussis vaccine. Since
1995, acellular vaccines were introduced, and in 1999 the
National Immunization Plan NIP (NIP) recommended the
combined DTaP (diphtheria, tetanus, and pertussis) vaccine
during the first year of age, and a booster dose at 5–6 y and
11–12 y of age. At national level, pertussis vaccination coverage
is high, being 94.63% in 2014.15
The diagnosis of pertussis still relies on clinical symptoms
and microbiological confirmation is rarely performed in the
country16; this situation determines an under-recognition and
under-notification.9 A recent retrospective analysis by Vittucci
et al17 analyzed the presence of pertussis among 215 infants
observed over a 3-years period and hospitalized for any acute
respiratory symptoms. Even without any specific selective clini-
cal criteria for pertussis, the authors found 24.7% of positivity
to pertussis. This finding emphasized the need in the use of lab-
oratory confirmation tests as criterion to confirm a suspected
pertussis case.
In our study, about 50% of infants with respiratory symp-
toms were positive for pertussis, following selective criteria of
ECDC case definition. Of them, 12% received one dose of acel-
lular vaccine; 4% had been received 2 doses of acellular vaccine,
even if the second doses were received only few days before the
onset of the symptoms, thus the infants were partially
immunized.
Paroxysmal cough, cyanosis, and apnea were strongly asso-
ciated with pertussis positivity. In particular, paroxysmal cough
was more likely reported among infants with positive samples
(p < 0.05; OR 1.96). An OR of 2.39 for post-cough vomiting,
together with cyanosis and apnea, was also found among per-
tussis positive patients. This suggests the occurrence of severe
manifestations among youngest infants with pertussis.
Respiratory syncytial virus (RSV) and rhinovirus were the
most frequent co-infections associated with pertussis
infection.18
Seventy-five percent of samples were lab-confirmed by PCR,
and 25% by both PCR and culture, emphasizing the role of
rapid diagnosis by molecular methods for a correct and prompt
management of pertussis case. On the other end, there is a
need to perform simultaneously B. pertussis culture to evaluate
the antimicrobials susceptibility and virulence associated genes,
since it might play a role in understanding the differences
among circulating pertussis isolates. All isolates had MICs
lower than those indicated for resistance, thus macrolide and in
particular clarithromycin remains the antibiotic of choice in
Italy for post-exposure prophylaxis and treatment of B. pertus-
sis infection.
Many studies have shown that variants have increased in
frequency after the introduction of vaccines and all currently
circulating strains have different genotypes from vaccine strains
regarding, in particular ptxA and prn genes. The B. pertussis
MT27 strain (double-locus variant of MT34) was the predomi-
nant type during the past decade in Australia,19 Europe,20
USA,21 and Japan.22 As described above, the MT27 expressing
prn2 and ptxP3 has been extensively described worldwide,
showing the potential to cause epidemics as a result of positive
selection in a highly vaccinated population.20 It was not sur-
prisingly that the pattern MT27 ptxA1-ptxP3-prn2, has been
found in unvaccinated infants.23
It is worth noting that the main molecular pattern identified
was associated with severe clinical manifestations in infants.
Clinical disease was not different among patients with pertac-
tin-deficient or pertactin-producing B. pertussis strains as also
recently demonstrated by Vodzak et al.24
This study has some limitations. Firstly, it was conducted in
a restricted hospital settings that would not be representative of
the whole country and also potentially biased by the selection
criteria requiring hospitalization. Secondly, it was not investi-
gated the post-infection follow-up in terms of microbiological
and immunological characterization. Nonetheless, our findings
may contribute to describe B. pertussis infection in unimmu-
nized population of small infants, underlining the need to use
appropriate laboratory diagnostic tests in all infants with respi-
ratory symptoms. B. pertussis virulence associated gene variants
should be evaluated among those cases with laboratory
confirmation.
In conclusion, B. pertussis infection remains a serious poten-
tial health risk to newborns, especially among those too young
to be vaccinated, who should be strictly monitored for the dis-
ease. The severity of the disease among infants should increase
the attention on pertussis, leading to better strategies for its pre-
vention and care. Taken together, our data are consistent and
reinforce a number of findings of other studies,4,18 comparing
culture and molecular assay.
Methods
Specimens and patients
Nasopharyngeal aspirates were collected from infants sequen-
tially admitted to 2 pediatric hospitals in Rome between August
2012 and March 2015. Eligible participants were children less
than 6 months of age, unvaccinated or partially vaccinated with
pertussis vaccine, presenting with an illness consistent with a
suspected pertussis or a lower respiratory tract infection. Clini-
cal criteria listed in the ECDC case definition,10 were used to
defined a suspected case of pertussis. In particular, paroxysms
of coughing, inspiratory “whooping,” post-tussive vomiting, or
Table 2. Molecular characteristics of 18 B. pertussis isolates.
ptxP prn2
MLVA Type ptxA1 ptxP1 ptxP3 producing deficient
MT 27 16 0 16 7 9
MT 28 1 0 1 1 0
MT 60 1 1 0 1 0
Total 18 1 17 9 9
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any person diagnosed as pertussis by a physician, or apneic epi-
sodes in infants, are included. For this analysis, clinical data
were collected using a standardized and dedicated question-
naire and database. In particular, information, i.e., on age, gen-
der, pertussis vaccination status, cough at admission (presence
and duration), paroxysmal cough, fever, apnea, cyanosis, was
collected.
Samples were sent within few hours after collection, at room
temperature, to the microbiology laboratory performing diag-
nosis and molecular characterization.
Bacterial culture and identification
B. pertussis cultivation was performed on Charcoal agar plates
(Oxoid, England) containing defibrinated sheep blood at 10%;
the plate were incubated at 37C up to 7 d and inspected daily.
For each sample, selective and non-selective medium contain-
ing cephalexin (40 mg/l) were used. Gram-staining determina-
tion and oxidase production assay were performed. The
identification was confirmed using specific anti-B. pertussis
agglutinating antiserum (Murex Diagnostics, France).
Antimicrobial susceptibility assay
The minimum inhibitory concentrations (MICs) were deter-
mined using the Etest assay25 for erythromycin, clarithromycin
and azithromycin (MIC Test Strip, Liofilchem Italy), following
standard’s. Isolates with MICs of > 256 mg/l after 72 h were
considered to be resistant.26
Molecular diagnosis
Chromosomal DNA was extracted using QIAamp DNA mini-
kit (QiaGEN, Hilden, Germany). The presence of B. pertussis,
B. parapertussis or B. bronchiseptica DNA was investigated
using 2 Bordetella Real Time PCR kits (Diagenode Diagnostics,
Liege, Belgium and Argene, bioMerieux, Marcy l’Etoile,
France); the targets are IS481 and IS1001, respectively. To pre-
vent misdiagnosis of B. holmesii as B. pertussis, all samples posi-
tive for B. pertussis were confirmed with a specific Real Time
PCR assay for B. pertussis using the ptxP (promoter of pertussis
toxin gene) as target.27 All Real Time PCR assay was performed
using the LightCycler 2.0 (Roche Diagnostic). Data were ana-
lyzed with LightCycler software (version 4.0, Roche
Diagnostic).
Molecular characterization
Sequence based typing was performed on DNAs extracted from
bacterial isolates or clinical samples, using the QIAamp DNA
minikit (QiaGEN, Hilden, Germany). The genes of pertactin,
(prn), pertussis toxin promoter (ptxP) and pertussis toxin sub-
unit A (ptxA) were sequenced using the method described pre-
viously.11,28 Full length pertactin gene sequencing was
performed on viable isolates using primers and protocol as
described previously.12 PCR amplifications were carried out
using Mastercycler personal thermal cycler (Eppendorff, Ham-
burg, Germany). All amplification products were analyzed by
electrophoresis and purified with QIAquick purification
columns kit (QIAGEN) for subsequent sequence analysis by
Sanger method. Sequences were analyzed with BLAST (http://
blast.ncbi.nlm.nih.gov/Blast.cgi) or MUSCLE (http://www.ebi.
ac.uk/Tools/msa/muscle/).
MLVA
Multilocus variable number tandem repeat (VNTR) analysis
(MLVA) was carried out on 18 B. pertussis isolates. To deter-
mine the repeat count for each locus, the sequence of 6 loci was
performed as described previously,28 The assignment of MLVA
type was based on the combination of repeat counts for VNTRs
1, 3a, 3b, 4, 5, and 6 and was consistent with international
nomenclature (http://www.mlva.net/).
Statistical analysis
Anonymized data were analyzed using Epiinfo software vers
3.5. Comparison was done by using Odds Ratios (OR) with
95% confidence intervals (95% CI); statistical significance was
set at p value < 0.05.
Ethics approval
The study was reviewed and approved by the Ospedale Pedia-
trico Bambino Gesu Institutional Review Board (Protocol num-
ber 150 LB).
Abbreviations
ACV acellular vaccine
ECDC European Centre for Disease Prevention and Control
MIC minimum inhibitory concentrations
MLVA Multilocus variable number tandem repeat analysis
NPA nasopharyngeal aspirate
prn pertactin
ptxA subunit S1 of the pertussis toxin
ptxP promoter of the pertussis toxin gene
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